Effects of paroxetine combined with low-dose quetiapine in the treatment of somatic symptom disorders
Objective To investigate the clinical efficacy and safety of paroxetine combined with low-dose quetiapine in the treatment of patients with somatic symptom disorders. Methods A total of 98 patients with somatic symptom disorders from June 2022 to December 2023 in Nanjing Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine were randomly divided into a study group (50 cases,7 dropouts) and a control group (48 cases,5 dropouts) by using a random number table method. The control group was treated with paroxetine hydrochloride,while the study group was treated with low-dose quetiapine in addition to paroxetine. The Patient Health Questionnaire-15 (PHQ-15) was used to assess the efficacy of somatic symptom treatment in both groups before treatment and at the end of weeks 2 and 4. The Hamilton Anxiety Rating Scale (HAMA-14) was used to evaluate the anxiety symptoms of the patients,and the Treatment Emergent Symptom Scale (TESS) was employed to assess adverse reactions during the treatment period. Results Before treatment,there were no statistically significant differences in PHQ-15 and HAMA-14 scores between the two groups (P>0.05). At the end of weeks 2 and 4 after treatment,the PHQ-15 and HAMA-14 scores in both groups decreased compared to those before treatment. The PHQ-15 and HAMA-14 scores in the study group were lower than those in the control group at the end of weeks 2 and 4 after treatment,with statistical-ly significant differences (P<0.05). There was no statistically significant difference in TESS scores between the two groups at weeks 2 and 4 after treatment (P>0.05). Conclusion The combination of paroxetine and low-dose que-tiapine in the treatment of pa-tients with somatic symptom disorder can enhance therapeutic efficacy without in-creasing adverse drug reactions.
Somatic symptom disordersQuetiapine fumarateParoxetineAnxietyDrug-related side effects and adverse reactions
万方数据
维普
